6533b826fe1ef96bd1283dc2

RESEARCH PRODUCT

Procalcitonin for the diagnosis of invasive candidiasis: what is the evidence?

Pasquale IozzoFilippo VitaleAntonino GiarratanoAndrea CortegianiSanti Maurizio Raineri

subject

medicine.medical_specialtySepsiInvasive candidiasiCritical Care and Intensive Care MedicineProcalcitoninSepsis03 medical and health sciences0302 clinical medicineAntibiotic therapySepsismedicine030212 general & internal medicineIntensive care medicineLetter to the EditorCandida spp.Surrogate endpointbusiness.industrylcsh:Medical emergencies. Critical care. Intensive care. First aid030208 emergency & critical care medicineInvasive candidiasislcsh:RC86-88.9medicine.diseasebacterial infections and mycosesCandida spp.; Invasive candidiasis; Procalcitonin; Sepsis; Critical Care and Intensive Care MedicinePredictive valueInvasive candidiasisCandida sppbusinessProcalcitoninhormones hormone substitutes and hormone antagonists

description

Abstracts Procalcitonin is a widely used marker for the evaluation of infection and sepsis and to guide antibiotic therapy. During the last decade, several studies evaluated its role and diagnostic performance as a surrogate marker for the identification of Candida spp. in suspected invasive candidiasis. A low serum level and a favorable negative predictive value are the main findings for procalcitonin in this setting. The aim of this report is to provide an updated brief summary of the evidence supporting the use of PCT for the management of invasive candidiasis.

yearjournalcountryeditionlanguage
2017-08-11Journal of Intensive Care
10.1186/s40560-017-0252-xhttp://link.springer.com/article/10.1186/s40560-017-0252-x